Abstract
Background and purpose
Randomized trials confirmed the efficacy and the safety of hypofractionated whole breast irradiation (HF-WBI) in patients with early-stage breast cancer. However, the role of HF-WBI in patients with DCIS after breast conserving surgery has not yet been clearly established in prospective randomized trials. The aim of this study was to evaluate if HF-WBI can be considered comparable to conventionally fractionated (CF)-WBI in DCIS patients.
Materials and methods
The analysis included DCIS patients from four Italian centers treated with CF-WBI 50 Gy/25 fractions or HFRT 40.5 Gy/15 fractions, without tumor bed boost. A propensity score matching (PSM) analysis was performed using a logistic regression that considered age, grading, presence of necrosis, resection margin status and adjuvant endocrine therapy.
Results
Five hundred twenty-seven patients was included (367 in the CF-WBI-group and 160 in the HR-WBI group). After 1:1 matching, 101 patients were allocated to the CF-WBI-group and 104 to the HF-WBI group. No correlation was observed between the type of RT schedule and LRFS (HR 1.68, 95% CI 0.82–3.45; p = 0.152). After PSM, no statistical difference was observed between the two RT group (HR 1.11, 95% CI 0.40–3.04; p = 0.833), with 3- and 5-years LRFS rates of 100% and 97.9% for CF-WBI and 95.6% and 94% for HF-WBI.
Conclusion
A short course of radiation therapy seems to be comparable to CF-WBI in terms of clinical outcomes. These data support the use of hypofractionated schedules in DCIS patients, but considering the remaining uncertainties.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Austin PC (2011) an introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 46:399–424. https://doi.org/10.1080/00273171.2011.568786
Cante D et al (2014) Hypofractionation and concomitant boost to deliver adjuvant whole-breast radiation in ductal carcinoma in situ (DCIS): a subgroup analysis of a prospective case series. Med Oncol 31:838. https://doi.org/10.1007/s12032-014-0838-2
Ciervide R, Dhage S, Guth A, Shapiro RL, Axelrod DM, Roses DF, Formenti SC (2012) Five year outcome of 145 patients with ductal carcinoma in situ (DCIS) after accelerated breast radiotherapy. Int J Radiat Oncol Biol Phys 83:e159–e164. https://doi.org/10.1016/j.ijrobp.2011.11.025
Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. L. Erlbaum Associates, Hillsdale
Cuzick J et al (2011) Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol 12:21–29. https://doi.org/10.1016/S1470-2045(10)70266-7
De Rose F et al (2018) Hypofractionated volumetric modulated arc therapy in ductal carcinoma in situ: toxicity and cosmetic outcome from a prospective series. Br J Radiol 91:20170634. https://doi.org/10.1259/bjr.20170634
Donker M et al (2013) Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol 31:4054–4059. https://doi.org/10.1200/JCO.2013.49.5077
Guenzi M et al (2013) Two different hypofractionated breast radiotherapy schedules for 113 patients with ductal carcinoma in situ: preliminary results. Anticancer Res 33:3503–3507
Hathout L et al (2013) Hypofractionated radiation therapy for breast ductal carcinoma in situ. Int J Radiat Oncol Biol Phys 87:1058–1063. https://doi.org/10.1016/j.ijrobp.2013.08.026
Haviland JS et al (2013) The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 14:1086–1094. https://doi.org/10.1016/S1470-2045(13)70386-3
Isfahanian N, Al-Hajri T, Marginean H, Chang L, Caudrelier JM (2017) Hypofractionation is an acceptable alternative to conventional fractionation in the treatment of postlumpectomy ductal carcinoma in situ with radiotherapy. Clin Breast Cancer 17:e77–e85. https://doi.org/10.1016/j.clbc.2016.10.005
Kerlikowske K (2010) Epidemiology of ductal carcinoma in situ. J Natl Cancer Inst Monogr 2010:139–141. https://doi.org/10.1093/jncimonographs/lgq027
King MT et al (2020) Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3–07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial. Lancet Oncol 21:685–698. https://doi.org/10.1016/S1470-2045(20)30085-1
Lalani N et al (2014) Long-term outcomes of hypofractionation versus conventional radiation therapy after breast-conserving surgery for ductal carcinoma in situ of the breast. Int J Radiat Oncol Biol Phys 90:1017–1024. https://doi.org/10.1016/j.ijrobp.2014.07.026
McCormick B et al (2015) RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol 33:709–715. https://doi.org/10.1200/JCO.2014.57.9029
Meattini I et al (2019) A national multicenter study on 1072 DCIS patients treated with breast-conserving surgery and whole breast radiotherapy (COBCG-01 study). Radiother Oncol 131:208–214. https://doi.org/10.1016/j.radonc.2018.07.015
Mokbel K, Cutuli B (2006) Heterogeneity of ductal carcinoma in situ and its effects on management. Lancet Oncol 7:756–765. https://doi.org/10.1016/S1470-2045(06)70861-0
Murray Brunt A et al (2020) Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet 395:1613–1626. https://doi.org/10.1016/S0140-6736(20)30932-6
Nilsson C, Valachis A (2015) The role of boost and hypofractionation as adjuvant radiotherapy in patients with DCIS: a meta-analysis of observational studies. Radiother Oncol 114:50–55. https://doi.org/10.1016/j.radonc.2015.01.001
Offersen BV et al (2020) Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomized phase III trial: the DBCG HYPO trial. J Clin Oncol 38:3615–3625. https://doi.org/10.1200/JCO.20.01363
Olivotto IA et al (2020) International comparison of cosmetic outcomes of breast conserving surgery and radiation therapy for women with ductal carcinoma in situ of the breast. Radiother Oncol 142:180–185. https://doi.org/10.1016/j.radonc.2019.07.024
Owen JR et al (2006) Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol 7:467–471. https://doi.org/10.1016/S1470-2045(06)70699-4
Rakovitch E et al (2007) The management of ductal carcinoma in situ of the breast: a screened population-based analysis. Breast Cancer Res Treat 101:335–347. https://doi.org/10.1007/s10549-006-9302-0
Rosenbaum PR, Rubin DB (1983) The central role of the propensity score in observational studies for causal effects. Biometrika 70:41–55. https://doi.org/10.2307/2335942
Sanders ME, Schuyler PA, Dupont WD, Page DL (2005) The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 103:2481–2484. https://doi.org/10.1002/cncr.21069
Smith BD et al (2018) Radiation therapy for the whole breast: executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol 8:145–152. https://doi.org/10.1016/j.prro.2018.01.012
Wallis MG, Clements K, Kearins O, Ball G, Macartney J, Lawrence GM (2012) The effect of DCIS grade on rate, type and time to recurrence after 15 years of follow-up of screen-detected DCIS. Br J Cancer 106:1611–1617. https://doi.org/10.1038/bjc.2012.151
Wapnir IL et al (2011) Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 103:478–488. https://doi.org/10.1093/jnci/djr027
Warnberg F et al (2014) Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS trial. J Clin Oncol 32:3613–3618. https://doi.org/10.1200/JCO.2014.56.2595
Whelan TJ et al (2010) Long-term results of hypofractionated radiation therapy for breast cancer. New Eng J Med 362:513–520. https://doi.org/10.1056/NEJMoa0906260
Williamson D, Dinniwell R, Fung S, Pintilie M, Done SJ, Fyles AW (2010) Local control with conventional and hypofractionated adjuvant radiotherapy after breast-conserving surgery for ductal carcinoma in-situ. Radiother Oncol 95:317–320. https://doi.org/10.1016/j.radonc.2010.03.021
Yarnold J et al (2005) Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol 75:9–17. https://doi.org/10.1016/j.radonc.2005.01.005
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
Ethics Committee was not consulted because of the retrospective nature of the study and all the procedures being performed were part of the routine care.
Informed consent
Informed consent was obtained from all individual patients.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
De Rose, F., De Santis, M., Meduri, B. et al. Comparing hypofractionated and conventionally fractionated whole breast irradiation for patients with ductal carcinoma in situ after breast conservation: a propensity score-matched analysis from a national multicenter cohort (COBCG-02 study). J Cancer Res Clin Oncol 147, 2069–2077 (2021). https://doi.org/10.1007/s00432-020-03483-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-020-03483-5